Document Detail


Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
MedLine Citation:
PMID:  10545429     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND:Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS:In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardial infarction), INJECT (INternational Joint Efficacy Comparison of Thrombolytics), and GUSTO-3 (Global Use of Strategies To Open occluded coronary arteries) trials, 126 patients were enrolled in a single center. Patients were treated with either conventional alteplase (100 mg/180 min; n=15), accelerated alteplase (100 mg/90 min; n=21), reteplase 10+10-U double bolus (n=50), reteplase 10+5-U double bolus (n=15), reteplase 15-U single bolus (n=15), or streptokinase (1.5 MU/60 min; n=10). PA (after stimulation with ADP), P-selectin expression and fibrinogen binding to glycoprotein (GP) IIb/IIIa (determined by flow cytometry with and without stimulation with ADP), and levels of soluble P-selectin, prothrombin fragments F1 and F2, thrombin-antithrombin complexes (TAT), and antithrombin III (ATIII) were determined. PA decreased significantly at 1 and 2 hours in patients treated by 10+10-U reteplase or by streptokinase. Fibrinogen binding to platelet GP IIb/IIIa followed a similar pattern. Significant thrombin generation and significantly elevated thrombin levels during thrombolysis were reflected by increased F1 and F2 fragments and TAT levels in all treatment groups. ATIII levels decreased significantly during thrombolytic therapy. CONCLUSIONS:A decrease in PA in patients treated by reteplase or streptokinase compared with alteplase could be observed in the early phase. Double bolus (10+10 U) reteplase and streptokinase resulted in lower PA at 1 and 2 hours than therapy with accelerated alteplase. Total fibrinogen and fibrinogen binding to GP IIb/IIIa tended to be lower during the first 2 hours after reteplase than after accelerated alteplase.
Authors:
M Moser; T Nordt; K Peter; J Ruef; B Kohler; M Schmittner; R Smalling; W Kübler; C Bode
Related Documents :
8759069 - Beneficial effects of rheothrx injection in patients receiving thrombolytic therapy for...
1739049 - Thrombolytic therapy in acute myocardial infarction.
7480969 - Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
1729879 - Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients ...
7904119 - Early intravenous beta blockade and thrombolytics in acute myocardial infarction.
17640539 - Thrombolysis in acute myocardial infarction: current status.
22423609 - Innate immunity markers in culprit plaques of acute myocardial infarction or stable ang...
24628869 - Mechanical ventricular assist device as a bridge to recovery post abo incompatible hear...
9630099 - Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 japane...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Circulation     Volume:  100     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  1999 Nov 
Date Detail:
Created Date:  1999-11-18     Completed Date:  1999-11-18     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1858-64     Citation Subset:  AIM; IM    
Affiliation:
Internal Medicine III (Cardiology), University of Heidelberg, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Double-Blind Method
Fibrinogen / metabolism*
Humans
Middle Aged
Myocardial Infarction / blood,  drug therapy*
P-Selectin / metabolism
Platelet Activation / drug effects*
Platelet Aggregation / drug effects*
Platelet Glycoprotein GPIIb-IIIa Complex / metabolism*
Protein Binding
Recombinant Proteins / therapeutic use
Streptokinase / therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use
Chemical
Reg. No./Substance:
0/P-Selectin; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 133652-38-7/reteplase; 9001-32-5/Fibrinogen; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular effects of estrogen and vitamin E therapies in postmenopausal women.
Next Document:  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass...